ClinicalTrials.gg
CompletedNCT05948592REVERSE2Updated Dec 22, 2025

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

A Phase 2 interventional study of TP-102 and Placebo in Diabetic Foot Infection, sponsored by Technophage, SA. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Technophage, SA · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Diabetic Foot with a site in India — 2 open to participants now, 2 under way, none of them phase 3. Diabetic Foot · India.

Enrollment
12th of 17
76 · median 120
Started
2023
with 1 other
Phase 2
2 of 18
none open now
Registered
13th of 18
by date
Lead sponsor
1 of 18
Technophage, SA

Among the 18 studies in Diabetic Foot with a site in India, this one is the 12th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 2, and was the 13th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

2 of the 18 studies in Diabetic Foot with a site in India are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Diabetic Foot with a site in India, or all of them as a file.
02

Study summary

TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical treatment of patients with wound infections including chronic ulcers; applied every other day (three times weekly (TIW)).

Read the detailed description

This is a Phase 2b, double-blinded, randomised, placebo-controlled multicenter study to determine the safety and efficacy of TP-102, in patients with diabetic foot infection.

Eighty (80) patients with an infected diabetic foot ulcer and with at least one target bacterial strain (Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii) susceptible to TP-102.

Patients will be randomised to receive TP-102 or placebo, in a 1:1 ratio. Patients will be treated with 1 (one) mL of IP/ Placebo solution applied topically per cm3 of target ulcer. Patients will be treated with a total of 12 treatments in 28 days (+3 days) with at least one day of interval in between the days of treatment (no consecutive days of treatment are allowed) and a maximum of 3 (three) days without treatment.

The titre of each bacteriophage in TP-102 is 1x109 (>1x108 and \< 1x1010) plaque forming units per milliliter (PFU/mL).

Assessments for efficacy and safety will include concomitant medications and AEs, local tolerability, clinical laboratory tests, vital signs, physical examination, wound biopsy/swab to determine the presence, speciation and TP-102 sensitivity of bacteria and target ulcer assessment.

03

Conditions studied

  • Diabetic Foot Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years old;
  • Established diagnosis of Diabetes Mellitus (type I or II);
  • Glycosylated () value \< 12.0%;
  • Designated foot infection meets the following criteria:
  • Present for at least 3 weeks;
  • Below-ankle, full-thickness, cutaneous ulcer;
  • Wound area (after debridement, if applicable) 1 to 20.0 cm2;
  • PEDIS infection grade 2 or 3;
  • PEDIS perfusion grade 1 or 2;
  • PEDIS depth grade 1 or 2 (grade 3 at the discretion of the investigator e.g. if they have received appropriate surgical treatment to remove infected bones).
  • Diabetic foot infection with at least one target bacterial strain (Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii), susceptible to the TP-102 bacteriophage cocktail, as assessed from wound cultures;
  • Patients of suitable physical and mental health as determined by the Investigator on the basis of medical history and general physical examination;
  • Patients of must have a negative serum pregnancy test at screening;
  • ICF signed voluntarily before any study-related procedure is performed, indicating that the patient understands the purpose of, and procedures required in the study and is willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Infected study ulcer less than 2 cm away from other ulcers, in the case of multiple ulcers;
  • Patient receiving hyperbaric oxygen therapy (HBOT), negative pressure wound therapy (NPWT), bioengineering skin (BES) substitutes and/or growth factors;
  • Patient which, in the opinion of the investigator, may not comply with study related procedures;
  • Presence of active malignant or benign tumors of any kind, (with exception to nonmelanoma skin cancer as per investigator's discretion);
  • Being pregnant or breastfeeding;
  • Currently participating in another clinical trial or having participated in a previous clinical trial with receipt of an product within 30 days of the first administration of IP;
  • A condition that, in the opinion of the Investigator, could compromise the well-being of the patient or course of the study, or prevent the patient from meeting or performing any study requirements;
  • Participants with to any component of investigational products.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    TP-102

    Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms at Day 1. The wound standard of care (SoC) procedures shall be in accordance to each sites normal DFI routine.

    Biological: TP-102

  • Placebo comparator
    Placebo

    Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms at Day 1. The wound standard of care (SoC) procedures shall be in accordance to each sites normal DFI routine.

    Other: Placebo

Interventions

  • BiologicalTP-102

    Patients randomised to TP-102 will receive 1 (one) mL of IP solution, applied topically per cm3 of target ulcer. The titre of each bacteriophage in TP-102 is 1x109 PFU/mL (\>1x108 PFU/mL and \<1x1010 PFU/mL). All patients randomised to TP-102 will receive the same concentration per mL. TP-102 will be applied to the target ulcer using a syringe without a needle. The volume of TP-102 to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).

  • OtherPlacebo

    Patients randomised to placebo, the volume calculated to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).

06

What researchers measure

Primary outcomes

  1. 1. Number and percentage of treatment emergent adverse events (TEAEs)

    See above

    Time frame: From baseline to EOT, aproximately 12 weeks

  2. 2. Mean DFUWI score (total AUC) for TP-102 versus Placebo

    See above

    Time frame: From baseline to EOT, , aproximately 12 weeks

  3. 3. Percentage of patients that achieve a 50% reduction in wound surface area by week 4

    Time frame: Week 4

Secondary outcomes

  1. 1. Change in mean CRP/ESR/PCT/WCC value for TP-102 versus Placebo

    Time frame: From baseline to EOT, , aproximately 12 weeks

  2. 2. Percentage of patients with a value over clinical diagnostic cut-off for DFI for CRP/ESR/PCT/WCC

    Time frame: Baseline to EOT, , aproximately 12 weeks

  3. 3. Percentage eradication of TP-102 susceptible strains for TP-102 versus Placebo at EOT;

    Time frame: EOT, , aproximately 12 weeks

  4. 4. Percentage of patients with target strain not-susceptible to TP-102 for TP-102 versus Placebo at EOT;

    Time frame: EOT, , aproximately 12 weeks

07

Study locations

10 sites
  • Clemente Clinical Research
    Los Angeles, California 90033, United States
  • Tranquil Clinical Research
    Webster, Texas 77598, United States
  • MV Hospital for Diabetes Pvt. Ltd
    Chennai, 600013, India
  • GSVM Medical College
    Kanpur, India
  • Crescent Hospital & Heart Centre
    Nagpur, 440012, India
  • Shree Siddhi Vinayak Hospital
    Nashik, 422002, India
  • Jupiter Hospital & Research Center
    Vadodara, 390012, India
  • Parikh Multispeciality Healthcare Pvt. Ltd
    Vadodara, 390020, India
  • Aman Hospital & Research Centre
    Vadodara, 390021, India
  • Yalamanchi Hospitals & Research Centers Pvt. Ltd
    Vijayawada, 520002, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Oct 2025, 23 months.

Of 31 phase 2 interventional studies under Diabetic Foot, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Jul 17, 2023
StartActual
Nov 8, 2023
Primary completionActual
Oct 30, 2025
CompletionActual
Dec 19, 2025
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05948592
Lead sponsor
Technophage, SA
Collaborators
VectorB2B
Responsible party
Sponsor
First posted
Jul 17, 2023
Start date
Nov 8, 2023
Primary completion
Oct 30, 2025
Completion
Dec 19, 2025
Last update
Dec 22, 2025

Study contacts

Sachin Arsule
principal investigator · Shree Siddhi Vinayal Hospital
Yalamanchi Rao
principal investigator · Yalamanchi Hospitals & Research Centers Pvt. Ltd
Senthil Kumar
principal investigator · MV Hospital for Diabetes Pvt. Ltd
Aman Khanna
principal investigator · Aman Hospital & Research Centre
Mohammad Qureshi
principal investigator · Crescent Hospital & Heart Centre
Parikh Niranjan
principal investigator · Parikh Multispeciality Healthcare Pvt. Ltd
Sanjay Kala
principal investigator · GSVM Medical College
Vikas Matai
principal investigator · Jupiter Hospital & Research Centre
Stan Mathis, PI
principal investigator · Clemente Clinical Research
Abdul Moosa, PI
principal investigator · Tranquil Clinical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion